VLP Conjugate Vaccines for Multivalent Antigen Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current multivalent vaccines face challenges such as protein overload and limited protection against additional serotypes, as they rely on a single protein carrier and are time-consuming to develop, leaving gaps in immunity against emerging pathogens.
Innovation Solution
Development of multivalent vaccines using virus-like particles (VLPs) conjugated with multiple polysaccharides representing various serotypes, which reduces antigen misfolding and protein load, and can be administered without adjuvants, providing broad and strong immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If a single protein carrier is used in multivalent polysaccharide conjugate vaccines, then the vaccine can be manufactured with current technology, but the protein load becomes enormous and causes protein overload in patients
Solution Approach 1:
The patent changes the carrier protein from a single protein type to virus-like particles (VLPs) which are self-assembling viral structural components. This parameter change allows the vaccine to maintain multivalency while significantly reducing the total protein load required, as VLPs can be produced in large quantities through viral replication systems without requiring excessive amounts of carrier protein
Solution Approach 2:
The patent uses composite VLP structures that can simultaneously display multiple different polysaccharide antigens on their surface. This composite approach allows a single VLP particle to serve as a carrier for multiple antigens, reducing the need for separate protein carriers for each antigen and thereby reducing overall protein load
2Adaptability or versatility
If multiple polysaccharide antigens are conjugated to a single protein carrier, then multivalent protection is achieved, but antigen misfolding and capsid misassembly occur
Solution Approach 1:
The patent segments the antigen display onto separate VLP particles rather than conjugating all antigens to a single protein carrier. Each VLP can be independently assembled with specific polysaccharide antigens, ensuring proper antigen folding and capsid assembly while maintaining multivalent protection through the presence of multiple VLP particles with different antigen combinations
Solution Approach 2:
The patent uses VLPs as intermediary structures that facilitate proper antigen display. The VLP framework provides a stable platform that guides correct antigen folding and assembly, acting as a mediator between the polysaccharide antigens and the immune system, thereby preventing misfolding and misassembly issues
3Reliability
If conventional polysaccharide conjugate vaccines are used, then protection is provided against vaccinated serotypes, but pathogens not represented in the vaccine become more predominant
Solution Approach 1:
The patent creates universal VLP-based vaccine platforms that can display multiple different polysaccharide antigens representing various serotypes on a single vaccine formulation. This multi-functionality allows the vaccine to provide protection against both currently circulating and emerging serotypes simultaneously, as the VLP structure can be configured to present multiple antigen types without compromising the stability or immunogenicity of individual antigens
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The VLP-conjugate vaccines offer reduced antigen and protein requirements, generating effective humoral and cellular immune responses, providing protection against multiple serotypes with lower doses and avoiding side effects, making them suitable for children and infants.
Implementation Method 1
VLP's are formed from the self-assembly of structural proteins of selected groups of viruses. These proteins self-assembly into a capsule
Implementation Method 2
Other VLPs have been used as carriers for foreign antigens, including non-protein antigens, via chemical conjugation
Data Source
AI summary
The invention is directed to vaccines comprising capsular polysaccharides conjugated to one or more components of virus like particles (VLP), and methods for the administration of and methods for the manufacture of vaccines of the invention. Preferably vaccines of the invention generate a therapeutically effective response in an individual in need thereof to multiple strains and/or serotypes of the same or of different infectious agents. Preferably such vaccines generate a therapeutically effective immune response to all pathogenic strains and/or serotypes of the same infectious agent. In particular, the invention is directed to methods and compositions for the cost efficient administration of a vaccine to a patient in need thereof exposing the patient's immune system to only the immunogenic components that are likely to be beneficial for the generation of a protective immunological response, both efficacy and safety are increased and cost effectively.